In fact, the expression levels of the molecular target for immunotherapeutic drugs such as nivolumab and pembrolizumab - PD-L1 - are higher on intra-cranial compared with extra-cranial melanoma metastases 27. This evidence concerns the gene CD274 and melanoma.